BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18207161)

  • 1. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
    Friedman M; Orlova A; Johansson E; Eriksson TL; Höidén-Guthenberg I; Tolmachev V; Nilsson FY; Ståhl S
    J Mol Biol; 2008 Mar; 376(5):1388-402. PubMed ID: 18207161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.
    Friedman M; Nordberg E; Höidén-Guthenberg I; Brismar H; Adams GP; Nilsson FY; Carlsson J; Ståhl S
    Protein Eng Des Sel; 2007 Apr; 20(4):189-99. PubMed ID: 17452435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo.
    Lindborg M; Cortez E; Höidén-Guthenberg I; Gunneriusson E; von Hage E; Syud F; Morrison M; Abrahmsén L; Herne N; Pietras K; Frejd FY
    J Mol Biol; 2011 Mar; 407(2):298-315. PubMed ID: 21277312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
    Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
    Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
    Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
    Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT; Reist CJ; Foulon CF; Lorimer IA; Archer G; Pegram CN; Pastan I; Zalutsky MR; Bigner DD
    Clin Cancer Res; 1999 Jun; 5(6):1539-49. PubMed ID: 10389943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe.
    Diagaradjane P; Orenstein-Cardona JM; Colón-Casasnovas NE; Deorukhkar A; Shentu S; Kuno N; Schwartz DL; Gelovani JG; Krishnan S
    Clin Cancer Res; 2008 Feb; 14(3):731-41. PubMed ID: 18245533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thermodynamic mixing of molecular states of the epidermal growth factor receptor modulates macroscopic ligand binding affinity.
    Holbrook MR; Slakey LL; Gross DJ
    Biochem J; 2000 Nov; 352 Pt 1(Pt 1):99-108. PubMed ID: 11062062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
    Orlova A; Magnusson M; Eriksson TL; Nilsson M; Larsson B; Höidén-Guthenberg I; Widström C; Carlsson J; Tolmachev V; Ståhl S; Nilsson FY
    Cancer Res; 2006 Apr; 66(8):4339-48. PubMed ID: 16618759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of an optimized scaffold for affibody molecules.
    Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
    J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.
    Tolmachev V; Nilsson FY; Widström C; Andersson K; Rosik D; Gedda L; Wennborg A; Orlova A
    J Nucl Med; 2006 May; 47(5):846-53. PubMed ID: 16644755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
    Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry.
    Tolmachev V; Friedman M; Sandström M; Eriksson TL; Rosik D; Hodik M; Ståhl S; Frejd FY; Orlova A
    J Nucl Med; 2009 Feb; 50(2):274-83. PubMed ID: 19164241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts.
    Humphrey PA; Wong AJ; Vogelstein B; Friedman HS; Werner MH; Bigner DD; Bigner SH
    Cancer Res; 1988 Apr; 48(8):2231-8. PubMed ID: 3258189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of ((4-hydroxyphenyl)ethyl)maleimide for site-specific radiobromination of anti-HER2 affibody.
    Mume E; Orlova A; Larsson B; Nilsson AS; Nilsson FY; Sjöberg S; Tolmachev V
    Bioconjug Chem; 2005; 16(6):1547-55. PubMed ID: 16287254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of novel EGFR-specific VHH domains.
    Gottlin EB; Xiangrong Guan ; Pegram C; Cannedy A; Campa MJ; Patz EF
    J Biomol Screen; 2009 Jan; 14(1):77-85. PubMed ID: 19171923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of cell motility by interaction of gangliosides, tetraspanins, and epidermal growth factor receptor in A431 versus KB epidermoid tumor cells.
    Park SY; Yoon SJ; Freire-de-Lima L; Kim JH; Hakomori SI
    Carbohydr Res; 2009 Aug; 344(12):1479-86. PubMed ID: 19559406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.